Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non‑small cell lung cancer (Review)
- Authors:
- Li Wang
- Wen Wang
-
Affiliations: Shanghai R&D Center, Jiangsu Simcere Pharmaceutical Co., Ltd., Shanghai 201318, P.R. China - Published online on: November 13, 2020 https://doi.org/10.3892/or.2020.7851
- Pages: 13-28
-
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Duffy MJ and O'Byrne K: Tissue and blood biomarkers in lung cancer: A review. Adv Clin Chem. 86:1–21. 2018. View Article : Google Scholar | |
|
Khan M, Lin J, Liao G, Tian Y, Liang Y, Li R, Liu M and Yuan Y: ALK inhibitors in the treatment of ALK positive NSCLC. Front Oncol. 8:5572019. View Article : Google Scholar | |
|
Melosky B, Cheema P, Agulnik J, Albadine R, Bebb DG, Blais N, Burkes R, Butts C, Card PB, Chan AMY, et al: Canadian perspectives: Update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer. Curr Oncol. 25:317–328. 2018. View Article : Google Scholar | |
|
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar | |
|
Chan BA and Hughes BG: Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future. Transl Lung Cancer Res. 4:36–54. 2015. | |
|
D'Arcangelo M, Wynes MW and Hirsch FR: The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer. Curr Opin Oncol. 25:121–129. 2013. View Article : Google Scholar | |
|
Huang H: Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase: A catalytic receptor with many faces. Int J Mol Sci. 19:34482018. View Article : Google Scholar | |
|
Golding B, Luu A, Jones R and Viloria-Petit AM: The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer. 17:522018. View Article : Google Scholar | |
|
Roskoski R Jr: Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers. Pharmacol Res. 117:343–356. 2017. View Article : Google Scholar | |
|
Zhang Z, Guo H, Lu Y, Hao W and Han L: Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: A meta-analysis. J Thorac Dis. 11:1397–1409. 2019. View Article : Google Scholar | |
|
Sgambato A, Casaluce F, Maione P and Gridelli C: Targeted therapies in non-small cell lung cancer: A focus on ALK/ROS1 tyrosine kinase inhibitors. Expert Rev Anticancer Ther. 18:71–80. 2018. View Article : Google Scholar | |
|
Cui S, Zhao Y, Gu A, Ge X, Song Y, Zhang W, Lou Y, Dong L, Han B and Jiang L: Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patients. Med Oncol. 32:6262015. View Article : Google Scholar | |
|
Califano R, Greystoke A, Lal R, Thompson J and Popat S: Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer. Lung Cancer. 111:51–58. 2017. View Article : Google Scholar | |
|
Zhu V and Ou SH: Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer. Expert Opin Drug Saf. 16:509–514. 2017. View Article : Google Scholar | |
|
Sabari JK, Santini FC, Schram AM, Bergagnini I, Chen R, Mrad C, Lai WV, Arbour KC and Drilon A: The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers. Onco Targets Ther. 10:1983–1992. 2017. View Article : Google Scholar | |
|
Bauer TM, Felip E, Solomon BJ, Thurm H, Peltz G, Chioda MD and Shaw AT: Clinical management of adverse events associated with lorlatinib. Oncologist. 24:1103–1110. 2019. View Article : Google Scholar | |
|
Spagnuolo A, Maione P and Gridelli C: Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: From the first- to third-generation of ALK inhibitors. Expert Opin Emerg Drugs. 23:231–241. 2018. View Article : Google Scholar | |
|
Gadgeel SM: The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer. Future Oncol. 14:1875–1882. 2018. View Article : Google Scholar | |
|
Vavala T and Novello S: Alectinib in the treatment of ALK-positive non-small cell lung cancer: An update on its properties, efficacy, safety and place in therapy. Ther Adv Med Oncol. 10:17588359187893642018. View Article : Google Scholar | |
|
Paik J and Dhillon S: Alectinib: A review in advanced, ALK-positive NSCLC. Drugs. 78:1247–1257. 2018. View Article : Google Scholar | |
|
Cortinovis D, Canova S, Abbate MI, Colonese F, Cogliati V and Bidoli P: Challenges in ALK inhibition of ALK-positive non-small-cell lung cancer: From ALK positivity detection to treatment strategies after relapse. Future Oncol. 14:2303–2317. 2018. View Article : Google Scholar | |
|
Peters S and Zimmermann S: Management of resistance to first-line anaplastic lymphoma kinase tyrosine kinase inhibitor therapy. Curr Treat Options Oncol. 19:372018. View Article : Google Scholar | |
|
Dagogo-Jack I and Shaw AT: Crizotinib resistance: Implications for therapeutic strategies. Ann Oncol. 27 (Suppl 3):iii42–iii50. 2016. View Article : Google Scholar | |
|
Ali R, Arshad J, Palacio S and Mudad R: Brigatinib for ALK-positive metastatic non-small-cell lung cancer: Design, development and place in therapy. Drug Des Devel Ther. 13:569–580. 2019. View Article : Google Scholar | |
|
Bedi S, Khan SA, AbuKhader MM, Alam P, Siddiqui NA and Husain A: A comprehensive review on Brigatinib-A wonder drug for targeted cancer therapy in non-small cell lung cancer. Saudi Pharm J. 26:755–763. 2018. View Article : Google Scholar | |
|
Pfizer Inc.: XALKORI 2011, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202570s028lbl.pdfJanuary 10–2019 | |
|
Xu H, O'Gorman M, Boutros T, Brega N, Kantaridis C, Tan W and Bello A: Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects. J Clin Pharmacol. 55:104–113. 2015. View Article : Google Scholar | |
|
Hamilton G, Rath B and Burghuber O: Pharmacokinetics of crizotinib in NSCLC patients. Expert Opin Drug Metab Toxicol. 11:835–842. 2015. View Article : Google Scholar | |
|
Fujiwara Y, Hamada A, Mizugaki H, Aikawa H, Hata T, Horinouchi H, Kanda S, Goto Y, Itahashi K, Nokihara H, et al: Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism. Cancer Sci. 107:1117–1123. 2016. View Article : Google Scholar | |
|
El-Khoueiry AB, Sarantopoulos J, O'Bryant CL, Ciombor KK, Xu H, O'Gorman M, Chakrabarti J, Usari T and El-Rayes BF: Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer. Cancer Chemother Pharmacol. 81:659–670. 2018. View Article : Google Scholar | |
|
Tan W, Yamazaki S, Johnson TR, Wang R, O'Gorman MT, Kirkovsky L, Boutros T, Brega NM and Bello A: Effects of renal function on crizotinib pharmacokinetics: Dose recommendations for patients with ALK-positive non-small cell lung cancer. Clin Drug Investig. 37:363–373. 2017. View Article : Google Scholar | |
|
Hirota T, Muraki S and Ieiri I: Clinical pharmacokinetics of anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer. Clin Pharmacokinet. 58:403–420. 2019. View Article : Google Scholar | |
|
Pirker R and Filipits M: From crizotinib to lorlatinib: Continuous improvement in precision treatment of ALK-positive non-small cell lung cancer. ESMO Open. 4:e0005482019. View Article : Google Scholar | |
|
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar | |
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar | |
|
Nishio M, Kim DW, Wu YL, Nakagawa K, Solomon BJ, Shaw AT, Hashigaki S, Ohki E, Usari T, Paolini J, et al: Crizotinib versus chemotherapy in asian patients with ALK-positive advanced non-small cell lung cancer. Cancer Res Treat. 50:691–700. 2018. View Article : Google Scholar | |
|
Deeks ED: Ceritinib: A review in ALK-positive advanced NSCLC. Target Oncol. 11:693–700. 2016. View Article : Google Scholar | |
|
Tomasini P, Egea J, Souquet-Bressand M, Greillier L and Barlesi F: Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: Clinical trial evidence and experience with a focus on brain metastases. Ther Adv Respir Dis. 13:17534666198319062019. View Article : Google Scholar | |
|
Claxton L, O'Connor J, Woolacott N, Wright K and Hodgson R: Ceritinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer: An evidence review group evaluation of a NICE single technology appraisal. Pharmacoeconomics. 37:645–654. 2019. View Article : Google Scholar | |
|
Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, et al: The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 4:662–673. 2014. View Article : Google Scholar | |
|
Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, et al: Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 370:1189–1197. 2014. View Article : Google Scholar | |
|
Gainor JF and Shaw AT: Fast, food and ceritinib in ALK-positive NSCLC. J Thorac Oncol. 12:1341–1343. 2017. View Article : Google Scholar | |
|
Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, et al: First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomised, open-label, phase 3 study. Lancet. 389:917–929. 2017. View Article : Google Scholar | |
|
Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, et al: Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 18:874–886. 2017. View Article : Google Scholar | |
|
Beardslee T and Lawson J: Alectinib and brigatinib: New second-generation ALK inhibitors for the treatment of non-small cell lung cancer. J Adv Pract Oncol. 9:94–101. 2018. | |
|
Parrott NJ, Yu LJ, Takano R, Nakamura M and Morcos PN: Physiologically based absorption modeling to explore the impact of food and gastric pH changes on the pharmacokinetics of alectinib. AAPS J. 18:1464–1474. 2016. View Article : Google Scholar | |
|
Novello S, Mazieres J, Oh IJ, de Castro J, Migliorino MR, Helland Å, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter A, et al: Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: Results from the phase III ALUR study. Ann Oncol. 29:1409–1416. 2018. View Article : Google Scholar | |
|
Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, et al: Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): An open-label, randomised phase 3 trial. Lancet. 390:29–39. 2017. View Article : Google Scholar | |
|
Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, et al: Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 377:829–838. 2017. View Article : Google Scholar | |
|
Umbela S, Ghacha S, Matuknauth R, Gause S, Joshee S and Deshmukh RR: Brigatinib: New-generation ALK inhibitor for nonsmall cell lung cancer. Curr Probl Cancer. 43:1004772019. View Article : Google Scholar | |
|
Markham A: Brigatinib: First global approval. Drugs. 77:1131–1135. 2017. View Article : Google Scholar | |
|
Tugnait M, Gupta N, Hanley MJ, Sonnichsen D, Kerstein D, Dorer DJ, Venkatakrishnan K and Narasimhan N: Effects of strong CYP2C8 or CYP3A inhibition and CYP3A induction on the pharmacokinetics of brigatinib, an oral anaplastic lymphoma kinase inhibitor, in healthy volunteers. Clin Pharmacol Drug Dev. 9:214–223. 2020. View Article : Google Scholar | |
|
Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, et al: Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 379:2027–2039. 2018. View Article : Google Scholar | |
|
Al-Salama ZT and Keam SJ: Entrectinib: First global approval. Drugs. 79:1477–1483. 2019. View Article : Google Scholar | |
|
Genentech Inc: ROZLYTREK 2019. simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212726s000lbl.pdfJanuary 10–2019 | |
|
Wang Q, Fang P, Zheng L and Ye L: Quantification and pharmacokinetic study of entrectinib in rat plasma using ultra-performance liquid chromatography tandem mass spectrometry. Biomed Chromatogr. 33:e44672019. | |
|
Liu D, Offin M, Harnicar S, Li BT and Drilon A: Entrectinib: An orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Ther Clin Risk Manag. 14:1247–1252. 2018. View Article : Google Scholar | |
|
Pfizer Inc: Lorbrena 2018. simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdfJanuary 10–2019 | |
|
Akamine T, Toyokawa G, Tagawa T and Seto T: Spotlight on lorlatinib and its potential in the treatment of NSCLC: The evidence to date. Onco Targets Ther. 11:5093–5101. 2018. View Article : Google Scholar | |
|
Li W, Sparidans RW, Wang Y, Lebre MC, Wagenaar E, Beijnen JH and Schinkel AH: P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. Int J Cancer. 143:2029–2038. 2018. View Article : Google Scholar | |
|
Wu YL, Lu S, Lu Y, Zhou J, Shi YK, Sriuranpong V, Ho JCM, Ong CK, Tsai CM, Chung CH, et al: Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in east asian patients with ALK-positive advanced non-small cell lung cancer. J Thorac Oncol. 13:1539–1548. 2018. View Article : Google Scholar | |
|
Yoneda KY, Scranton JR, Cadogan MA, Tassell V, Nadanaciva S, Wilner KD and Stollenwerk NS: Interstitial lung disease associated with crizotinib in patients with advanced non-small cell lung cancer: Independent review of four PROFILE trials. Clin Lung Cancer. 18:472–479. 2017. View Article : Google Scholar | |
|
Shah RR, Morganroth J and Shah DR: Hepatotoxicity of tyrosine kinase inhibitors: Clinical and regulatory perspectives. Drug Saf. 36:491–503. 2013. View Article : Google Scholar | |
|
Liu B, Yuan M, Sun Y, Cheng Z, Zhang Z, Hou S, Wang X and Liu J: Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: A systematic review and meta-analysis. Oncotarget. 9:9480–9488. 2017. View Article : Google Scholar | |
|
Costa RB, Costa RLB, Talamantes SM, Kaplan JB, Bhave MA, Rademaker A, Miller C, Carneiro BA, Mahalingam D and Chae YK: Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer. Oncotarget. 9:22137–22146. 2018. View Article : Google Scholar | |
|
Zhu Q, Hu H, Weng DS, Zhang XF, Chen CL, Zhou ZQ, Tang Y and Xia JC: Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC. BMC Cancer. 17:4122017. View Article : Google Scholar | |
|
Zhu VW, Lu Y and Ou SI: Severe acute hepatitis in a patient receiving alectinib for ALK-positive non-small-cell lung cancer: Histologic analysis. Clin Lung Cancer. 20:e77–e80. 2019. View Article : Google Scholar | |
|
Jung D, Han JM, Yee J, Kim JY and Gwak HS: Factors affecting crizotinib-induced hepatotoxicity in non-small cell lung cancer patients. Med Oncol. 35:1542018. View Article : Google Scholar | |
|
Van Sebille YZ, Gibson RJ, Wardill HR and Bowen JM: ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: Chloride secretion as a mechanistic hypothesis. Cancer Treat Rev. 41:646–652. 2015. View Article : Google Scholar | |
|
Schaefer ES and Baik C: Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer. Cancer Manag Res. 8:33–38. 2016. View Article : Google Scholar | |
|
Ariad, . ALUNBRIG. 2017. simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208772lbl.pdfJanuary 10–2019 | |
|
Pellegrino B, Facchinetti F, Bordi P, Silva M, Gnetti L and Tiseo M: Lung toxicity in non-small-cell lung cancer patients exposed to ALK inhibitors: Report of a peculiar case and systematic review of the literature. Clin Lung Cancer. 19:e151–e161. 2018. View Article : Google Scholar | |
|
Gemma A, Kusumoto M, Kurihara Y, Masuda N, Banno S, Endo Y, Houzawa H, Ueno N, Ohki E and Yoshimura A: Interstitial lung disease onset and its risk factors in Japanese patients with ALK-positive NSCLC after treatment with crizotinib. J Thorac Oncol. 14:672–682. 2019. View Article : Google Scholar | |
|
Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, et al: Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: A single-arm, open-label, phase 1/2 trial. Lancet Oncol. 17:1683–1696. 2016. View Article : Google Scholar | |
|
Domenech M, Jove M, Aso S, Marin M and Nadal E: Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease. Lung Cancer. 119:99–102. 2018. View Article : Google Scholar | |
|
Novartis Inc: Zykadia, . 2014, simplehttps://www.pharma.us.novartis.com/product/pi/pdf/zykadia.pdfJanuary 10–2019 | |
|
Hoffmann-La Roche: ALECENSA. 2015. simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdfJanuary 10–2019 | |
|
Morcos PN, Bogman K, Hubeaux S, Sturm-Pellanda C, Ruf T, Bordogna W, Golding S, Zeaiter A, Abt M and Balas B: Effect of alectinib on cardiac electrophysiology: Results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies. Cancer Chemother Pharmacol. 79:559–568. 2017. View Article : Google Scholar |
